Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216028 | 0.86 | OPRM1 (0.56) | ADRA1DSLC6A4 | |
| SCHEMBL13261751 | 0.85 | HTR2C (0.68) | ADRA1DSLC6A4KDM4EATMCYP2D6 | |
| SCHEMBL14306777 | 0.82 | ADRA1D (0.80) | ADRA1DSLC6A4KDM4EATMCYP2D6 | |
| SCHEMBL7214363 | 0.82 | OPRL1 (0.76) | ADRA1DSLC6A4 | |
| SCHEMBL7216288 | 0.82 | OPRL1 (0.48) | ADRA1D | |
| SCHEMBL7221132 | 0.81 | ADRA1D (0.57) | ADRA1DSLC6A4CYP2D6KMT2A | |
| Oxalic Acid SCHEMBL7215994 | 0.81 | OPRM1 (0.53) | ADRA1DSLC6A4KDM4E | |
| SCHEMBL4475225 | 0.80 | ADRA1D (0.67) | ADRA1DSLC6A4KDM4EATMCYP2D6 | |
| SCHEMBL25759842 | 0.80 | ADRA1D (0.67) | ADRA1DSLC6A4KDM4EATMCYP2D6 | |
| SCHEMBL7213861 | 0.79 | OPRL1 (0.58) | ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| CN-1246117-A | 1, 2-indane or indoline derivatives | LUNDBECK & CO AS H (DK) | 2000-03-01 | — | — | CN | disclosed |
| EP-0946542-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028293-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H.LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | ADRA1D 22/4885SLC6A4 40/4885KDM4E 1773/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | ADRA1D 22/4885SLC6A4 40/4885KDM4E 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.